Bionano Genomics, Inc. (NASDAQ:BNGO) Sees Large Increase in Short Interest

Bionano Genomics, Inc. (NASDAQ:BNGO) saw a significant growth in short interest in September. As of September 15th, there was short interest totaling 706,400 shares, a growth of 113.2% from the August 31st total of 331,300 shares. Currently, 9.8% of the company’s stock are sold short. Based on an average trading volume of 499,300 shares, the short-interest ratio is presently 1.4 days. Based on an average trading volume of 499,300 shares, the short-interest ratio is presently 1.4 days. Currently, 9.8% of the company’s stock are sold short.

Bionano Genomics Stock Up 1.6%

BNGO opened at $1.92 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.41 and a current ratio of 1.76. Bionano Genomics has a fifty-two week low of $1.50 and a fifty-two week high of $28.14. The firm’s fifty day moving average is $3.03 and its 200 day moving average is $3.40. The stock has a market cap of $7.95 million, a price-to-earnings ratio of -0.01 and a beta of 2.19.

Bionano Genomics (NASDAQ:BNGO) last released its earnings results on Thursday, August 14th. The company reported ($1.99) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.69) by $0.70. Bionano Genomics had a negative net margin of 271.02% and a negative return on equity of 129.41%. The company had revenue of $6.73 million for the quarter, compared to analysts’ expectations of $6.90 million. Bionano Genomics has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS.

Analysts Set New Price Targets

BNGO has been the subject of several analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Bionano Genomics in a research report on Saturday, September 27th. Wall Street Zen raised shares of Bionano Genomics from a “sell” rating to a “hold” rating in a research report on Monday, August 25th. Finally, HC Wainwright reissued a “buy” rating and set a $11.00 price target (up previously from $10.00) on shares of Bionano Genomics in a research report on Monday, August 18th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $7.50.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bionano Genomics stock. Jane Street Group LLC bought a new stake in shares of Bionano Genomics, Inc. (NASDAQ:BNGO) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 410,469 shares of the company’s stock, valued at approximately $118,000. Jane Street Group LLC owned approximately 21.05% of Bionano Genomics as of its most recent filing with the Securities and Exchange Commission. 11.35% of the stock is currently owned by institutional investors.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.